ANAB
AnaptysBio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANAB
Anaptysbio, Inc.
A clinical-stage biotechnology company focused on innovative immunology therapeutics
10770 Wateridge Circle, Suite 210, San Diego, CA 92121
--
AnaptysBio, Inc., established in Delaware in November 2005. The company is a clinical-stage biotechnology company focused on delivering innovative immunological therapies. The Company is developing immune cell regulating antibodies, including two wholly-owned checkpoint agonists in clinical stage development for autoimmune and inflammatory diseases: rosnilimab, a Phase 2 trial of the Company's PD-1 agonist for the treatment of moderate to severe rheumatoid arthritis (" RA ") and a Phase 2 trial for the treatment of moderate to severe ulcerative colitis (" UC "); ANB032, the Company's BTLA agonist, Phase 2 trial for the treatment of moderate to severe atopic dermatitis (" AD ").
Company Financials
EPS
ANAB has released its 2025 Q3 earnings. EPS was reported at 0.52, versus the expected -1.25, beating expectations. The chart below visualizes how ANAB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ANAB has released its 2025 Q3 earnings report, with revenue of 76.32M, reflecting a YoY change of 154.26%, and net profit of 15.11M, showing a YoY change of 146.00%. The Sankey diagram below clearly presents ANAB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
